← All patents

US20230139944A1

Targeting alpha3beta1 integrin for treatment of cancer and other diseases

University of Texas System

Abstract

Provided herein, in some aspects, are agents, such as antibodies, chimeric antigen receptors, or RNA interference molecules that target the interaction between α3β1 integrin and α1 homotrimeric type I collagen. Aspects are directed to methods of treating cancer and fibroids comprising …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
Raghu Kalluri
Priority date
June 21, 2019
Filing date
June 17, 2020
Publication date
May 04, 2023
Language
en
Metadata fetched
August 29, 2026 00:30